Jonathan Langley AppointmentAug 5, 2020ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience in Pulmonary Arterial Hypertension.
ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience in Pulmonary Arterial Hypertension.
ATXA Therapeutics Publishes Results of Phase 1 First-in-Human Study Evaluating the Safety & Tolerability of NTP42 in Healthy Volunteers